Endometrial cancer (EC) incidence and mortality rates have been increasing, particularly among young females. Although more than 90% of ECs are sporadic, 5–10% are hereditary, a majority of which occurs within Hereditary Non-Polyposis Colorectal Cancer syndrome (HNPCC) or Lynch syndrome. The traditional histopathological classification differentiates EC between two main groups: type I (or endometrioid) and type II (including all other histopathological subtypes). However, this classification lacks reproducibility and does not account for the emerging molecular heterogeneity. In 2013, The Cancer Genome Atlas (TCGA) project proposed EC molecular classification defining four groups with different prognostic and predictive values and the current international guidelines are progressively establishing EC risk stratification and treatment based on both histopathological and molecular criteria. Our manuscript aims to summarize the current state of EC molecular characterizations, including germline alterations at the basis of hereditary EC predisposition, to discuss their clinical utility as prognostic and predictive markers.
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer / D'Agostino, E.; Mastrodomenico, L.; Ponzoni, O.; Baldessari, C.; Piombino, C.; Pipitone, S.; Giuseppa Vitale, M.; Sabbatini, R.; Dominici, M.; Toss, A.. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 126:(2024), pp. 102723-102734. [10.1016/j.ctrv.2024.102723]
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer
D'Agostino E.;Mastrodomenico L.;Ponzoni O.;Baldessari C.;Piombino C.;Pipitone S.;Dominici M.;Toss A.
2024
Abstract
Endometrial cancer (EC) incidence and mortality rates have been increasing, particularly among young females. Although more than 90% of ECs are sporadic, 5–10% are hereditary, a majority of which occurs within Hereditary Non-Polyposis Colorectal Cancer syndrome (HNPCC) or Lynch syndrome. The traditional histopathological classification differentiates EC between two main groups: type I (or endometrioid) and type II (including all other histopathological subtypes). However, this classification lacks reproducibility and does not account for the emerging molecular heterogeneity. In 2013, The Cancer Genome Atlas (TCGA) project proposed EC molecular classification defining four groups with different prognostic and predictive values and the current international guidelines are progressively establishing EC risk stratification and treatment based on both histopathological and molecular criteria. Our manuscript aims to summarize the current state of EC molecular characterizations, including germline alterations at the basis of hereditary EC predisposition, to discuss their clinical utility as prognostic and predictive markers.File | Dimensione | Formato | |
---|---|---|---|
CTR 2024.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
2.42 MB
Formato
Adobe PDF
|
2.42 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris